NCT02295059.

Trial name or title	Omega 3 fatty acids and ERPR(‐)HER2(±) breast cancer prevention
Methods	RCT
Participants	Women at risk for recurrent breast cancer‐ with prior diagnosis of stage 0 to III breast cancer and completion of surgery, chemotherapy or trastuzumab or radiation therapy
Interventions	Each for 12 months: Arm 1: omega‐3 high dose capsules (5 g/d EPA + DHA) Arm 2: omega‐3 low dose capsules (0.9 g/d EPA + DHA)
Outcomes	Primary: breast adipose tissue metabolites Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter methylation and pro‐inflammatory gene expression in mammary epithelial and adipose tissue
Starting date	Registered on trials registry: 14 October 2014 Study start date: August 2014 Estimated study completion date: January 2019
Contact information	Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes	NCT02295059